Vivesto ABOSTO:VIVE -3.40%26 ROA % is -16.87% as of Mar. 2026. GuruFocus rates OSTO:VIVE with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Vivesto AB ranks worse than 85.67% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vivesto AB's annualizedNet Income for the quarter that ended in Mar. 2026 was kr-27.57 Mil.
Vivesto AB's average Total Assets over the quarter that ended in Mar. 2026 was kr163.45 Mil. Therefore, Vivesto AB's annualized ROA % for the quarter that ended in Mar. 2026 was -16.87%.
The historical rank and industry rank for Vivesto AB's ROA % or its related term are showing as below:
OSTO:VIVE'
s ROA % Range Over the Past 10 Years
Min: -75.65 Med: -24.57 Max: -1.31
Current: -20.41
During the past 13 years, Vivesto AB's highest ROA % was -1.31%. The lowest was -75.65%. And the median was -24.57%.
OSTO:VIVE's ROA % is ranked worse than 85.67% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.72
vs OSTO:VIVE: -20.41
Vivesto AB (OSTO:VIVE) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Vivesto AB ROA % Related Terms
Vivesto AB ROA % Historical Data
* Premium members only.
The historical data trend for Vivesto AB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's ROA % distribution charts can be found below:
* The bar in red indicates where Vivesto AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Vivesto AB (OSTO:VIVE) has a ROA % of -16.87% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vivesto AB and its competitors. According to the industry distribution chart, Vivesto AB ranks #861 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Vivesto AB's ROA % too high?
Vivesto AB's current ROA % is -16.87%. Based on the distribution chart, Vivesto AB ranks #861 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #861 out of 1005 companies for ROA %. This places Vivesto AB in the lower half of its industry. The industry median ROA % is 2.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.72, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current ROA % is -16.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OSTO:VIVE) has a current ROA % of -16.87%. The current ROA % is -16.87%. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Vivesto AB (OSTO:VIVE), the current ROA % is -16.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OSTO:VIVE
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VIVE has been successfully added to your 
